Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14357880 | 1.00 | LMNA (0.80) | LMNATDP1ALDH1A1THRBCYP2C9 | |
| SCHEMBL1692380 | 1.00 | LMNA (0.80) | LMNATDP1ALDH1A1THRBCYP2C9 | |
| SCHEMBL12578884 | 1.00 | LMNA (0.80) | LMNATDP1ALDH1A1THRBCYP2C9 | |
| SCHEMBL23221679 | 0.92 | LMNA (0.66) | LMNATDP1ALDH1A1THRBCYP2C9 | |
| SCHEMBL23221677 | 0.92 | LMNA (0.66) | LMNATDP1ALDH1A1THRBCYP2C9 | |
| SCHEMBL20865712 | 0.91 | LMNA (0.76) | LMNATDP1ALDH1A1PSMB5ATM | |
| SCHEMBL19354974 | 0.91 | LMNA (0.76) | LMNATDP1ALDH1A1PSMB5ATM | |
| SCHEMBL20865763 | 0.91 | LMNA (0.76) | LMNATDP1ALDH1A1PSMB5ATM | |
| SCHEMBL13077323 | 0.91 | LMNA (0.76) | LMNATDP1ALDH1A1PSMB5ATM | |
| SCHEMBL5948087 | 0.89 | LMNA (0.63) | LMNATDP1ALDH1A1GAAPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010106550-A2 | A PROCESS FOR THE PREPARATION OF N-[[TRANS-4-(1-METHYLETHYL)CYCLOHEXYL]CARBONYL]-D-PHENYLALANINE | NEULAND LABORATORIES LTD. (IN) | 2010-09-23 | — | — | WO | claimed |
| US-7314955-B2 | Form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine | BIOCON LIMITED | 2008-01-01 | — | — | US | claimed |
| EP-1499586-A4 | NOVEL FORM OF N-(TRANS-4-ISOPROPYLCYCLOHEXYLCARBONYL)-D-PHENYLALANINE | BIOCON LTD (IN) | 2006-01-18 | — | — | EP | claimed |
| US-20050165108-A1 | reacting D-phenylalanine methylester HCl with trans-4-isopropylcyclohexane carboxylic acid in presence of propane phosphonic acid anhydride or LiOH Al2O3 in a halogenated hydrocarbon solvent such as dichloromethane or dichloroethane; type 2 diabetes mellitus | BIOCON LTD | 2005-07-28 | — | — | US | claimed |
| EP-1499586-A1 | NOVEL FORM OF N-(TRANS-4-ISOPROPYLCYCLOHEXYLCARBONYL)-D-PHENYLALANINE | Biocon Limited (IN) | 2005-01-26 | — | — | EP | claimed |
| WO-2003093222-A1 | NOVEL FORM OF N-(TRANS-4-ISOPROPYLCYCLOHEXYLCARBONYL)-D-PHENYLALANINE | BIOCON LIMITED (IN) | 2003-11-13 | — | — | WO | claimed |
| WO-2010106550-A2 | A PROCESS FOR THE PREPARATION OF N-[[TRANS-4-(1-METHYLETHYL)CYCLOHEXYL]CARBONYL]-D-PHENYLALANINE | NEULAND LABORATORIES LTD. (IN) | 2010-09-23 | — | — | WO | disclosed |
| WO-2008096373-A2 | PROCESS FOR SYNTHESIZING HIGHLY PURE NATEGLINIDE POLYMORPHS | IND-SWIFT LABORATORIES LIMITED (IN) | 2008-08-14 | — | — | WO | disclosed |
| US-7314955-B2 | Form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine | BIOCON LIMITED | 2008-01-01 | — | — | US | disclosed |
| WO-2007113650-A2 | A NOVEL AND IMPROVED PROCESS FRO THE PREPARATION OF NATEGLINIDE AND ITS POLYMORPH FORM-H | CADILA PHARMACEUTICALS LIMITED (IN) | 2007-10-11 | — | — | WO | disclosed |
| EP-1499586-A4 | NOVEL FORM OF N-(TRANS-4-ISOPROPYLCYCLOHEXYLCARBONYL)-D-PHENYLALANINE | BIOCON LTD (IN) | 2006-01-18 | — | — | EP | disclosed |
| US-20050165108-A1 | reacting D-phenylalanine methylester HCl with trans-4-isopropylcyclohexane carboxylic acid in presence of propane phosphonic acid anhydride or LiOH Al2O3 in a halogenated hydrocarbon solvent such as dichloromethane or dichloroethane; type 2 diabetes mellitus | BIOCON LTD | 2005-07-28 | — | — | US | disclosed |
| EP-1499586-A1 | NOVEL FORM OF N-(TRANS-4-ISOPROPYLCYCLOHEXYLCARBONYL)-D-PHENYLALANINE | Biocon Limited (IN) | 2005-01-26 | — | — | EP | disclosed |
| US-20040077725-A1 | Crystalline form of N-(trans-4-isopropylcyclohexane carbonyl)-D-phenylalanine and process for preparation thereof | DR. REDDY'S LABORATORIES LIMITED | 2004-04-22 | — | — | US | disclosed |
| WO-2004020396-A1 | CRYSTALLINE FORM OF NATEGLINIDE AND PROCESS FOR PREPARATION THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2004-03-11 | — | — | WO | disclosed |
| WO-2003093222-A1 | NOVEL FORM OF N-(TRANS-4-ISOPROPYLCYCLOHEXYLCARBONYL)-D-PHENYLALANINE | BIOCON LIMITED (IN) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077725-A1 | Crystalline form of N-(trans-4-isopropylcyclohexane carbonyl)-D-phenylalanine and process for preparation thereof | TTR, PREP, PEPD | LMNA 1099/4885TDP1 2055/4885ALDH1A1 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.